|
|
Volumn 5, Issue 5, 1998, Pages 415-424
|
|
Pharmacoeconomics of cancer therapy
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA2B INTERFERON;
AMIFOSTINE;
ANTINEOPLASTIC AGENT;
CAPECITABINE;
CARMUSTINE;
CISPLATIN;
DOCETAXEL;
DOLASETRON MESILATE;
GEMCITABINE;
IRINOTECAN;
NAVELBINE;
PACLITAXEL;
RAZOXANE;
RECOMBINANT INTERLEUKIN 11;
RETINOIC ACID;
RITUXIMAB;
TAMOXIFEN;
TOPOTECAN;
UNCLASSIFIED DRUG;
VINDESINE;
AUTOLOGOUS BONE MARROW TRANSPLANTATION;
BREAST CANCER;
CANCER SURVIVAL;
CANCER THERAPY;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
COST MINIMIZATION ANALYSIS;
COST UTILITY ANALYSIS;
HODGKIN DISEASE;
HUMAN;
LUNG NON SMALL CELL CANCER;
MELANOMA;
OVARY CANCER;
PHARMACOECONOMICS;
REVIEW;
TREATMENT OUTCOME;
|
|
EID: 0031769098
PISSN: 10732748
EISSN: None
Source Type: Journal
DOI: 10.1177/107327489800500504 Document Type: Review |
|
Times cited : (12)
|
|
References (23)
|
